Irrigation of Continent Catheterizable Ileal Pouches: Tap Water Can Replace Sterile Solutions Because It Is Safe, Easy, and Economical

Birkhäuser, Frédéric D.; Zehnder, Pascal; Roth, Beat; Schürch, Leander; Ochsner, Katharina; Willener, Rita; Thalmann, George N.; Burkhard, Fiona C.; Studer, Urs E.

doi:10.1016/j.eururo.2011.01.003

Cited by 24 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AB569: A Novel Bactericidal Agent Against All MDR Gram-Negative and Gram-Positive Bacteria Including the ESKAPE Pathogens Finally, AB569 is an innovative bactericidal combination of acidified nitrite (A-NO 2 − ) and Na 2 -EDTA, was patented by the corresponding author in 2018 (USPTO 9,925,206) and has great potential as a novel antimicrobial with broad spectrum activity against virtually all pathogenic bacteria. Regarding human use, the NaNO 2 and/or EDTA component(s) of AB569 have separately been proven safe in studies related to the treatment of cyanide poisoning (Bebarta et al, 2017), burn wounds (Wang et al, 2015), CF lung infection (Brown et al, 1985), urinary tract infection (Birkhauser et al, 2011), chelation therapy (Lanigan and Yamarik, 2002), and cosmetics (Juzeniene et al, 2007). Furthermore, both components of AB569 have been reported to increase the efficacy of certain antibiotics that are commonly used to treat a variety of infections (Zemke et al, 2014;Lebeaux et al, 2015;McDaniel et al, 2016), and individually to enhance the process of wound healing (Weller and Finnen, 2006;Wang et al, 2015).…”

Section: Conditions Of the Cf Airway Mucusmentioning

confidence: 99%

The Bactericidal Tandem Drug, AB569: How to Eradicate Antibiotic-Resistant Biofilm Pseudomonas aeruginosa in Multiple Disease Settings Including Cystic Fibrosis, Burns/Wounds and Urinary Tract Infections

et al. 2021

View full text Add to dashboard Cite

The life-threatening pandemic concerning multi-drug resistant (MDR) bacteria is an evolving problem involving increased hospitalizations, billions of dollars in medical costs and a remarkably high number of deaths. Bacterial pathogens have demonstrated the capacity for spontaneous or acquired antibiotic resistance and there is virtually no pool of organisms that have not evolved such potentially clinically catastrophic properties. Although many diseases are linked to such organisms, three include cystic fibrosis (CF), burn/blast wounds and urinary tract infections (UTIs), respectively. Thus, there is a critical need to develop novel, effective antimicrobials for the prevention and treatment of such problematic infections. One of the most formidable, naturally MDR bacterial pathogens is Pseudomonas aeruginosa (PA) that is particularly susceptible to nitric oxide (NO), a component of our innate immune response. This susceptibility sets the translational stage for the use of NO-based therapeutics during the aforementioned human infections. First, we discuss how such NO therapeutics may be able to target problematic infections in each of the aforementioned infectious scenarios. Second, we describe a recent discovery based on years of foundational information, a novel drug known as AB569. AB569 is capable of forming a “time release” of NO from S-nitrosothiols (RSNO). AB569, a bactericidal tandem consisting of acidified NaNO2 (A-NO2–) and Na2-EDTA, is capable of killing all pathogens that are associated with the aforementioned disorders. Third, we described each disease state in brief, the known or predicted effects of AB569 on the viability of PA, its potential toxicity and highly remote possibility for resistance to develop. Finally, we conclude that AB569 can be a viable alternative or addition to conventional antibiotic regimens to treat such highly problematic MDR bacterial infections for civilian and military populations, as well as the economical burden that such organisms pose.

show abstract

Section: Conditions Of the Cf Airway Mucusmentioning

confidence: 99%

The Bactericidal Tandem Drug, AB569: How to Eradicate Antibiotic-Resistant Biofilm Pseudomonas aeruginosa in Multiple Disease Settings Including Cystic Fibrosis, Burns/Wounds and Urinary Tract Infections

et al. 2021

View full text Add to dashboard Cite

show abstract

“…19 To reduce the prevalence of these strains, unnecessary antibiotic therapies must be avoided, also considering prophylactic measures and alternative treatments involving "non-antibiotic" agents. As a physical action, bladder irrigations using indwelling or intermittent catheterization might be offered as described by Birkhäuser et al 20 in a randomized controlled trial reporting that daily bladder irrigation applying tap water reduces the rate of antibiotic treatment in patients with ileal pouches._ENREF_21 Next generation DNA sequencing may improve diagnostic accuracy and enable direct targeting of bacterial biofilms to prevent recurrent UTIs by identifying bacteria which are not detectable using current techniques and by distinguishing bacterial strains with the capability of creating a…”

Section: Implications For Researchmentioning

confidence: 99%

The Challenge of Asymptomatic Bacteriuria and Symptomatic Urinary Tract Infections in Patients with Neurogenic Lower Urinary Tract Dysfunction

et al. 2020

View full text Add to dashboard Cite

PURPOSE We investigated prevalence of asymptomatic bacteriuria and incidence of symptomatic urinary tract infections (UTI) in patients with neurogenic lower urinary tract dysfunction (NLUTD) undergoing urodynamics and assessed predictors for symptomatic UTI. PATIENTS AND METHODS A prospective consecutive series of 317 patients (106 women, 211 men) with NLUTD was evaluated. Of them, 111 (35%) voided spontaneously, 141 (44%) relied on intermittent self-catheterization and 65 (21%) on an indwelling catheter. Before urodynamics, urine samples were collected by sterile catheterization for dipstick testing and urine culture. We assessed the association between patient characteristics and the occurrence of symptomatic UTIs following urodynamics in patients with asymptomatic bacteriuria and developed a prediction model based on the most important risk factors. RESULTS Urine cultures before urodynamics were negative in 123 (39%) and positive in 194 (61%) patients. (32%) and e (18%) were the most frequent bacteria. Of 194 patients with positive culture, 35 (18%) had at least one symptomatic UTI. In patients with a history of previous UTIs, the overall estimated probability of a symptomatic UTI was 45%, irrespective of the underlying neurological disorder. CONCLUSIONS About one out of five patients with asymptomatic bacteriuria will develop a symptomatic UTI in the follow-up year. This rather low overall probability precludes routine antibiotic prophylaxis or treatment in patients with NLUTD having asymptomatic bacteriuria as 4 out of 5 patients would be overtreated. However, in patients with a history of previous symptomatic UTIs antibiotic prescription might be justified.

show abstract

Checklists: Key Tips and What to Avoid

Studer

2014

Keys to Successful Orthotopic Bladder Substitution

View full text Add to dashboard Cite

Irrigation of Continent Catheterizable Ileal Pouches: Tap Water Can Replace Sterile Solutions Because It Is Safe, Easy, and Economical

Cited by 24 publications

References 17 publications

The Bactericidal Tandem Drug, AB569: How to Eradicate Antibiotic-Resistant Biofilm Pseudomonas aeruginosa in Multiple Disease Settings Including Cystic Fibrosis, Burns/Wounds and Urinary Tract Infections

The Bactericidal Tandem Drug, AB569: How to Eradicate Antibiotic-Resistant Biofilm Pseudomonas aeruginosa in Multiple Disease Settings Including Cystic Fibrosis, Burns/Wounds and Urinary Tract Infections

The Challenge of Asymptomatic Bacteriuria and Symptomatic Urinary Tract Infections in Patients with Neurogenic Lower Urinary Tract Dysfunction

Checklists: Key Tips and What to Avoid

Contact Info

Product

Resources

About